SCHEMBL22323936

SCHEMBL22323936

COCOc1cc(-c2ncc(C)o2)ccc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42
KDR P35968 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
MTOR P42345 1/20 0.42
PIK3CG P48736 1/20 0.42
EPHB4 P54760 1/20 0.42
PRKDC P78527 1/20 0.42
S1PR1 P21453 5/20 0.38
PTPN1 P18031 7/20 0.37
MET P08581 1/20 0.34
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAOB P27338 1/20 0.33
PRNP P04156 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447072 1.00 PIK3CD (0.42) PIK3CDABL1EGFRHCKSRC
SCHEMBL792274 0.80 PTPN1 (0.36) S1PR1PTPN1METKDM4ESMN1; SMN2
SCHEMBL22324200 0.78 ACHE (0.52) PIK3CDABL1EGFRHCKSRC
SCHEMBL30229053 0.78 CA12 (0.50) PIK3CDABL1EGFRHCKSRC
SCHEMBL31506704 0.78 ACHE (0.52) PIK3CDABL1EGFRHCKSRC
SCHEMBL30228940 0.78 PDE4A (0.41) PIK3CDABL1EGFRHCKSRC
SCHEMBL22323987 0.77 MET (0.33) S1PR1MET
SCHEMBL28694510 0.77 MET (0.33) EGFRS1PR1MET
SCHEMBL7820681 0.76 S1PR1 (0.44) S1PR1PTPN1METKDM4ESMN1; SMN2
SCHEMBL31488513 0.76 HPGD (0.57) PIK3CDABL1EGFRHCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 PIK3CD 2615/4885ABL1 3600/4885EGFR 4860/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 PIK3CD 3221/4885ABL1 3836/4885EGFR 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.